In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ardana Bioscience Ltd.

Latest From Ardana Bioscience Ltd.

Deal Watch: Aging-Focused Calico Taps Start-Up Terray For Discovery

Terray/Calico tie-up will focus on small molecule discovery for diseases of aging, including cancer. Lilly, AstraZeneca sign discovery pacts with Nimbus and Illumina, respectively.

Deal Watch Business Strategies

Keeping Track: Orphans Headline FDA Approvals; Gene Therapies Stand Out Among Submissions

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Approvals

Yakult's Japan Duvelisib Decision Casts New Shadow Over Shrinking Pharma Ops

Yakult’s decision to pull an approval application for duvelisib in Japan came shortly after a FDA advisory committee said it would re-evaluate the safety and efficacy of the PI3K inhibitor four years since its approval. The developments cast a new shadow over Yakult’s already-suffering pharmaceutical business.

Commercial Japan

Virios Fibromyalgia Drug Fails Phase IIb And Firm Says COVID-19 May Be To Blame

A Phase IIb trial testing IMC-1 for fibromyalgia failed to reach statistical significance on the primary pain endpoint, but one cohort showed an improvement and Virios intends to pursue the drug further.

Clinical Trials Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
UsernamePublicRestriction

Register